PPAR Research

Research Article

Antioxidant Potential of Adiponectin and Full PPAR-γ Agonist in Correcting Streptozotocin-Induced Vascular Abnormality in Spontaneously Hypertensive Rats

Table 2

Systemic hemodynamic parameters of WKY, SHR control, and SHR diabetic treated groups with irbesartan, pioglitazone, adiponectin, and a combination of adiponectin with irbesartan or pioglitazone.


Parameters	Groups	Days of observation
Parameters	Groups	Day 0	Day 8	Day 21	Day 28

Systolic blood pressure (mmHg)	WKY+CNT
	SHR+CNT	^!	^!	^!	^!
	SHR+STZ	^{^}	^{^}	^{^}	^{^}
	SHR+STZ+Irb			^δ	^δ
	SHR+STZ+Pio			^δж	^δж
	SHR+STZ+Adp			^#	^δ
	SHR+STZ+Irb+Adp			^δ	^δΦ
	SHR+STZ+Pio+Adp			^δ	^δ

Diastolic blood pressure (mmHg)	WKY+CNT
	SHR+CNT	^!	^!	^!	^!
	SHR+STZ
	SHR+STZ+Irb			^δ	^δ
	SHR+STZ+Pio			^δ
	SHR+STZ+Adp			^#ж	^δ#ж
	SHR+STZ+Irb + Adp			^δ	^δΦ
	SHR+STZ + Pio+Adp			^δ	^δ

Mean arterial pressure	WKY+CNT
	SHR+CNT	^!	^!	^!	^!
	SHR+STZ		^{^}	^{^}	^{^}
	SHR+STZ+Irb			^δ	^δ
	SHR+STZ+Pio			^δ	^δж
	SHR+STZ+Adp				^δ
	SHR+STZ+Irb+Adp			^δ	^δΦ
	SHR+STZ+Pio+Adp			^δ	^δ

Heart rate (BPM)	WKY+CNT
	SHR+CNT	^!	^!	^!	^!
	SHR+STZ	^{!^}	^{^}	^{^}	^{^}
	SHR+STZ+Irb		396 ± 4	393 ± 4^δ#	^δ#
	SHR+STZ+Pio			^δ	^δж
	SHR+STZ+Adp			^ж	^δ
	SHR+STZ+Irb+Adp			^δ	^δ
	SHR+STZ+Pio+Adp			^δ	^δ

Notes: the values are presented as the in each group and were analyzed by repeated measures one-way ANOVA followed by Bonferroni post hoc test. Values with were considered statistically significant. ! indicates significant difference () between the SHR and WKY control groups during and at the end of treatment. indicates significant difference () in comparison to day 0 of the respective group. δ indicates a significant difference () of the diabetic Irb, Pio, Adp, Irb+Adp, and Pio+Adp groups in comparison to the SHR diabetic control group. # indicates significant difference () between the diabetic Irb and Adp groups during and at the end of treatment. ж indicates significant difference () between the diabetic Pio and Adp groups during and at the end of treatment. Φ indicates significant difference () of the diabetic Adp group in comparison to the diabetic Irb+Adp group at days 21 and 28.